| Question 1: 1. Which of the following are alternate terms for radiopharmaceutical therapy? |
| Reference: | Jadvar H, et al. Radiotheranostics in Cancer Diagnosis and Management. Radiology 2018; 286(2): 388-400. |
| Choice A: | Molecular Targeted Radiotherapy |
| Choice B: | Radiotheranostics |
| Choice C: | Radionuclide Therapy |
| Choice D: | All of the Above |
| Question 2: Duties of an Authorized User include which of the following? |
| Reference: | Mettler FA Jr. and Guiberteau MJ. Essentials of Nuclear Medicine and Molecular Imaging, 7th Edition, 2019, Elsevier, Philadelphia, Chapter 13, pp. 382-401. |
| Choice A: | Written directive |
| Choice B: | Administration of the radiopharmaceutical |
| Choice C: | Record keeping |
| Choice D: | All of the above |
| Question 3: If a patient therapy is cancelled, which of the following cannot typically be decayed-in-storage? (Hint: One of these carries a radionuclidic impurity) |
| Reference: | U.S. NRC 10 CFR 35.92, https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0092.html |
| Choice A: | 90Y-microspheres |
| Choice B: | 131I-MIBG |
| Choice C: | 177Lu-DOTATATE |
| Choice D: | 223Ra dichloride |
| Question 4: Which of the following RPTs requires the most shielding during storage and administration? |
| Reference: | Smith DS, Stabin MG. Exposure rate constants and lead shielding values for over 1,100 radionuclides. Health physics. 2012 Mar 1;102(3):271-91. |
| Choice A: | 90Y-microspheres |
| Choice B: | 131I-MIBG |
| Choice C: | 177Lu-DOTATATE |
| Choice D: | 223Ra dichloride |
| Question 5: Radiopharmaceutical therapy dosimetry consists of: |
| Reference: | Loevinger R, Budinger TF, Watson EE. MIRD Primer for Absorbed Dose Calculation. New York Society of Nuclear Medicine, 1988. |
| Choice A: | Calculation of whole organ absorbed dose for prospective treatment planning and constraints on normal organ toxicity |
| Choice B: | Calculation of tumor absorbed dose for retrospective dose-response studies |
| Choice C: | Use of radiobiological, pharmacokinetic and small scale anatomical modeling |
| Choice D: | All of the above |
| Question 6: Added concerns and complications for targeted alpha-particle dosimetry over traditional beta-particle RPT dosimetry include: |
| Reference: | Sgouros G, Roeske, JC, McDevitt MR, Palm S, Allen BJ, Fisher, DR, H Song, RW Howell, G Akabani. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted Radionuclide Therapy. J Nucl Med. 2010 Feb;51(2):311-28. |
| Choice A: | A different biological response to dose (the RBE) |
| Choice B: | Low count rates in nuclear medicine imaging due to low amounts of administered activity |
| Choice C: | The short range of energy deposition can lead to localized dose distributions below the imaging resolution of SPECT or PET |
| Choice D: | Daughter isotopes are often radioactive, resulting in additional pharmacokinetics, distributions of activity, and dose |
| Choice E: | All of the above |
